Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 19717249)

1.

Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence.

Mauger S, Fraser R, Gill K.

Neuropsychiatr Dis Treat. 2014 Apr 7;10:587-98. doi: 10.2147/NDT.S39692. eCollection 2014. Review.

2.

Buprenorphine-naloxone therapy in pain management.

Chen KY, Chen L, Mao J.

Anesthesiology. 2014 May;120(5):1262-74. doi: 10.1097/ALN.0000000000000170. Review.

3.

State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.

Wen H, Cummings JR, Hockenberry JM, Gaydos LM, Druss BG.

JAMA Psychiatry. 2013 Dec;70(12):1355-62. doi: 10.1001/jamapsychiatry.2013.2169.

4.

Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.

Haddad MS, Zelenev A, Altice FL.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):127-35. doi: 10.1016/j.drugalcdep.2012.12.008. Epub 2013 Jan 17.

5.

Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?

Garcia-Portilla MP, Bobes-Bascaran MT, Bascaran MT, Saiz PA, Bobes J.

Br J Clin Pharmacol. 2014 Feb;77(2):272-84. doi: 10.1111/bcp.12031. Review.

6.

Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Savant JD, Barry DT, Cutter CJ, Joy MT, Dinh A, Schottenfeld RS, Fiellin DA.

Drug Alcohol Depend. 2013 Jan 1;127(1-3):243-7. doi: 10.1016/j.drugalcdep.2012.06.020. Epub 2012 Jul 6.

7.

Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.

Lofwall MR, Havens JR.

Drug Alcohol Depend. 2012 Dec 1;126(3):379-83. doi: 10.1016/j.drugalcdep.2012.05.025. Epub 2012 Jun 15.

8.

Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.

Edelman EJ, Dinh AT, Moore BA, Schottenfeld RS, Fiellin DA, Sullivan LE.

J Addict Med. 2012 Jun;6(2):159-65. doi: 10.1097/ADM.0b013e31824339fc.

9.

Addiction treatment-related employment barriers: the impact of methadone maintenance.

Richardson L, Wood E, Montaner J, Kerr T.

J Subst Abuse Treat. 2012 Oct;43(3):276-84. doi: 10.1016/j.jsat.2011.12.008. Epub 2012 Feb 1.

10.

Update on the clinical use of buprenorphine: in opioid-related disorders.

Ducharme S, Fraser R, Gill K.

Can Fam Physician. 2012 Jan;58(1):37-41. Review.

11.

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA.

J Gen Intern Med. 2012 Jun;27(6):669-76. doi: 10.1007/s11606-011-1962-8. Epub 2012 Jan 4.

12.

Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.

Fishman MJ, Wu LT, Woody GE.

Am J Psychiatry. 2011 Jul;168(7):675-9. doi: 10.1176/appi.ajp.2010.10060879. No abstract available.

13.

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.

Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.

Arch Intern Med. 2011 Mar 14;171(5):425-31. doi: 10.1001/archinternmed.2010.541.

14.

Update in addiction medicine for the generalist.

Gordon AJ, Kunins HV, Rastegar DA, Tetrault JM, Walley AY.

J Gen Intern Med. 2011 Jan;26(1):77-82. doi: 10.1007/s11606-010-1461-3. Epub 2010 Aug 10. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk